论文部分内容阅读
Cefpirome(HR810)是第三代头孢菌素的新衍生物,是一个抗菌谱很宽的药物,包括对头孢噻肟(Cefotaxime)和头孢他定(Cef tazidime)耐药菌株。作者通过男性健康志愿者,研究静脉一次和多次注射时的药代动力学、安全性和肾耐受性。药物2g每天注射2次,在第1次和第11次分别测定血清和尿中原药的浓度和计算药代动力学参数。药物测定用高效液相色谱法。第1次和第11次药物注后10分钟血清浓度分别为145.7±26.2和172.2±18.4mg/L;血清半衰期(t_(1/2)(?))分别为2.0±0.3h和1.8±0.2h;AUC∞276±23和307±30m·h/L总体消除率121±10
Cefpirome (HR810) is a new derivative of the third generation cephalosporin and is a very broad antimicrobial drug, including Cefotaxime and Cef tazidime resistant strains. The authors studied pharmacokinetics, safety, and renal tolerance in single and multiple injections of intravenous fluids through male healthy volunteers. Drug 2g injected twice a day, in the first and 11 were measured serum and urinary concentrations of the original drug and calculate the pharmacokinetic parameters. Drug determination by high performance liquid chromatography. The serum concentrations of the first and 11th drug injection after 10 minutes of injections were 145.7 ± 26.2 and 172.2 ± 18.4 mg / L, respectively. The serum half-lives (t_ (1/2)) were 2.0 ± 0.3h and 1.8 ± 0.2 h; AUC∞276 ± 23 and 307 ± 30m · h / L overall elimination rate of 121 ± 10